Database Query Results : , , JAK1

JAK1, Janus kinase 1: Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
One of the four members of the Janus kinase family and plays a significant role in the signaling pathways of various cytokines and growth factors, particularly those involved in immune responses. Its involvement in cancer has been increasingly recognized, as dysregulation of JAK1 signaling can contribute to tumorigenesis and cancer progression.
JAK1 is primarily associated with the signaling of several key cytokines, including interleukins (e.g., IL-2, IL-6, IL-10) and interferons. These cytokines are crucial for immune responses, and their dysregulation can lead to inhibitors, such as those targeting JAK1 specifically, are being investigated in clinical trials for various malignancies, including solid tumors and hematological cancers. an environment that supports cancer growth.
Scientific Papers found: Click to Expand⟱
176- Api,    Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells
- in-vitro, BC, BT474
cl‑Casp8↑, cl‑Casp3↑, p‑JAK1↓, p‑JAK2↓, p‑STAT3↓, P53↑, VEGF↓, Hif1a↓, MMP9↓,
1522- Ba,    Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production
- in-vitro, Nor, RAW264.7
*p‑STAT1↓, *p‑STAT3↓, *p‑JAK1↓, *p‑JAK2↓, *iNOS↓, *NO↓, *IL1β↓, *IL6↓, *TNF-α↓, *ROS↓,
2736- BetA,  Chemo,    Multifunctional Roles of Betulinic Acid in Cancer Chemoprevention: Spotlight on JAK/STAT, VEGF, EGF/EGFR, TRAIL/TRAIL-R, AKT/mTOR and Non-Coding RNAs in the Inhibition of Carcinogenesis and Metastasis
- Review, Var, NA
chemoPv↑, p‑STAT3↓, JAK1↓, JAK2↓, VEGF↓, EGFR↓, Cyt‑c↑, Diablo↑, AMPK↑, mTOR↓, Sp1/3/4↓, DNAdam↑, Gli1↓, GLI2↓, PTCH1↓, MMP2↓, MMP9↓, miR-21↓, SOD2↓, ROS↑, Apoptosis↑,
2853- FIS,    Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells
- in-vitro, Thyroid, TPC-1
Apoptosis↑, ROS↑, MMP↓, TumCCA↑, Casp3↑, Casp8↑, Casp9↑, JAK1↓, STAT3↓,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2↓, IAP2↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
822- GAR,    Garcinol, a Polyisoprenylated Benzophenone Modulates Multiple Proinflammatory Signaling Cascades Leading to the Suppression of Growth and Survival of Head and Neck Carcinoma
- vitro+vivo, HNSCC, NA
ROS↑, STAT3↓, cSrc↓, JAK1↓, JAK2↓, NF-kB↓, TGF-β↓, TumCG↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE/CCNE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1/CCND1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,
4793- Lyco,    Lycopene treatment inhibits activation of Jak1/Stat3 and Wnt/β-catenin signaling and attenuates hyperproliferation in gastric epithelial cells
- in-vitro, GC, AGS
antiOx↑, AntiCan↑, ROS↓, JAK1↓, STAT3↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, cycE/CCNE↓, TumCP↓, Risk↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
3047- SK,    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1/CCND1↓, cycE/CCNE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GPx↑, 2,   GSH↓, 1,   GSH↑, 1,   GSR↑, 1,   GSTA1↑, 1,   HO-1↑, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 2,   ROS↑, 4,   mt-ROS↑, 1,   SOD↑, 2,   SOD1↑, 1,   SOD2↓, 1,   SOD2↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   CDC25↓, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 3,   Glycolysis↓, 1,   HK2↓, 1,   PCK1↓, 1,   PPARγ↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↑, 4,   BAX↓, 1,   BAX↑, 2,   Bcl-2↓, 2,   Bcl-2↑, 1,   BIM↑, 1,   Casp↑, 1,   Casp3↑, 5,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp8↑, 3,   cl‑Casp8↑, 1,   Casp9↑, 2,   Chk2↓, 1,   Chk2↑, 1,   Cyt‑c↑, 3,   Diablo↑, 2,   DR5↑, 1,   Fas↑, 1,   IAP2↓, 1,   MAPK↓, 1,   MDM2↓, 1,   p‑p38↓, 1,   survivin↓, 2,  

Kinase & Signal Transduction ⓘ

cSrc↓, 2,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 3,  

Transcription & Epigenetics ⓘ

p‑H3↓, 1,   miR-21↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   p‑eIF2α↑, 2,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3s↑, 1,  

DNA Damage & Repair ⓘ

ATM↑, 1,   CHK1↓, 1,   CHK1↑, 1,   DNAdam↓, 1,   DNAdam↑, 2,   P53↓, 1,   P53↑, 2,   cl‑PARP↑, 4,   PCNA↓, 3,   γH2AX↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 2,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 3,   P21↑, 2,   RB1↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

cFos↓, 1,   cMET↓, 1,   EMT↓, 1,   ERK↓, 3,   p‑FOXO3↓, 1,   Gli1↓, 1,   GSK‐3β↑, 1,   mTOR↓, 3,   mTORC1↓, 1,   mTORC2↓, 1,   Nanog↓, 1,   OCT4↓, 1,   PTCH1↓, 1,   PTEN↑, 1,   RAS↓, 2,   SOX2↓, 1,   STAT3↓, 7,   p‑STAT3↓, 3,   TOP2↓, 1,   TumCG↓, 3,   Wnt↓, 2,  

Migration ⓘ

Ca+2↑, 1,   E-cadherin↑, 2,   GLI2↓, 1,   Ki-67↓, 2,   MMP13↓, 1,   MMP2↓, 2,   MMP7↓, 1,   MMP9↓, 4,   MMPs↓, 1,   N-cadherin↓, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 2,   TumCP↓, 4,   TumMeta↓, 2,   TumMeta↑, 1,   Twist↓, 1,   uPA↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   ATF4↑, 1,   EGFR↓, 3,   Hif1a↓, 1,   VEGF↓, 3,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IKKα↓, 1,   IL1↑, 1,   IL1β↓, 1,   IL2↑, 1,   IL4↑, 1,   IL6↓, 4,   IL8↓, 1,   Inflam↓, 1,   JAK1?, 1,   JAK1↓, 8,   p‑JAK1↓, 2,   JAK2↓, 4,   p‑JAK2↓, 2,   NF-kB↓, 5,   p65↓, 1,   PGE2↓, 2,   TNF-α↓, 3,   TNF-α↑, 1,  

Cellular Microenvironment ⓘ

ADAM17↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 3,   Dose↝, 2,   eff↓, 1,   Half-Life↓, 1,   Half-Life↝, 2,   RadioS↑, 2,  

Clinical Biomarkers ⓘ

EGFR↓, 3,   p‑HER2/EBBR2↓, 1,   IL6↓, 4,   Ki-67↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 2,   hepatoP↑, 1,   neuroP↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 2,   TumW↓, 1,  
Total Targets: 178

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSH↑, 1,   lipid-P↓, 1,   ROS↓, 1,  

Cell Death ⓘ

iNOS↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑STAT1↓, 1,   p‑STAT3↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   p‑JAK1↓, 1,   p‑JAK2↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,  
Total Targets: 16

Scientific Paper Hit Count for: JAK1, Janus kinase 1
2 Fisetin
2 Lycopene
1 Apigenin (mainly Parsley)
1 Baicalein
1 Betulinic acid
1 Chemotherapy
1 Garcinol
1 Honokiol
1 Piperlongumine
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:163  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page